Guest Columns & From The Editor

31. Driving Prostate Cancer Innovation Through Immunotherapy With OS Therapies' Dr. Robert Petit 9/26/2025

    OS Therapies' Dr. Robert Petit discusses the evolving role of immunotherapy in prostate cancer.

32. The Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation 9/26/2025

    Our recent Cell & Gene Live, Building The Future Of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, featuring expert panelists NKILT Therapeutics' Raphaël Ognar and NKore BioTherapeutics' Tracy Ryan covered the state of NK cell science, persistence challenges, safety, scalability, and the unique engineering breakthroughs shaping the future of oncology care.

33. Derisking AI Means First Asking: Who Does It Serve? 9/26/2025

    Ethical and accountability questions still swirl around how we use artificial intelligence in drug development.

34. A Study In Optimizing Late-Stage Processes With QbD, DoE 9/26/2025

    Nobody wants to redesign analytical process profiles when a market approval is within reach, but what about when a last-lap QbD exercise could bring real benefit?

35. On The Ground At BPI: Industry Reflections With Carl Schoellhammer, Ph.D. 9/25/2025

    DeciBio partner Carl Schoellhammer, Ph.D., speaks on the record with Bioprocess Online's chief editor Tyler Menichiello at the 2025 BioProcess International conference in Boston.

36. Key Considerations For Materials And Components Used In CGT Manufacturing 9/25/2025

    This article sheds light on the complexities and regulatory intricacies of ancillary materials and single-use systems in cell and gene therapy manufacturing.

37. Defining Strong Program Management In CDMO Partnerships 9/23/2025

    This first article of a planned three-part series discusses the pitfalls that program managers help sponsor companies avoid, how program managers accelerate timelines or reduce risk, and more.

38. CGT Success Starts With The First Mile 9/23/2025

    The so-called "last mile" in cell therapy gets a lot of attention. What about the first mile, the journey cells take between the donor and the manufacturing site?

39. Making The Leap To Smart Bioprocessing 9/19/2025

    A European consortium achieved greater T cell expansion compared to baseline conditions using real-time process monitoring and control.

40. Unlocking Method Insights For Novel Engineered AAV Capsids 9/18/2025

    Microfluidic platforms, such as labchip, are widely used for assessing wild type capsids. Now, engineered capsids are challenging these established workflows.